Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Randomized Study of Docetaxel With or Without NINTEDANIB (BIBF-1120) in Patient Receiving a First or Second-line of Chemotherapy for HER Negative Metastatic or Locally Recurrent Breast Cancer

NCT01658462 is registered in ClinicalTrials.gov with Centre Oscar Lambret as lead sponsor.

NCT NCT01658462
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01658462 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Randomized Study of Docetaxel With or Without NINTEDANIB (BIBF-1120) in Patient Receiving a First or Second-line of Chemotherapy for HER Negative Metastatic or Locally Recurrent Breast Cancer
Lead sponsor
Centre Oscar Lambret
Phase
Phase 2
Overall status
Completed
Start date
May 31, 2013
Completion date
October 30, 2017
Enrollment
51 (actual)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer